Recent Research Analysts’ Ratings Updates for Telix Pharmaceuticals (TLX)

Telix Pharmaceuticals (NASDAQ: TLX) has recently received a number of price target changes and ratings updates:

• 7/17/2026 – Telix Pharmaceuticals had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 7/17/2026 – Telix Pharmaceuticals was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”.
• 7/16/2026 – Telix Pharmaceuticals was given a new $18.00 price target by Royal Bank Of Canada.
• 7/7/2026 – Telix Pharmaceuticals had its price target lowered by Citigroup Inc. from $22.50 to $22.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Telix Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
• 7/6/2026 – Telix Pharmaceuticals had its “outperform” rating reaffirmed by Wedbush. They now have a $22.00 price target on the stock.

Insider Buying and Selling at Telix Pharmaceuticals

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch bought 33,435 shares of the firm’s stock in a transaction dated Wednesday, April 29th. The shares were purchased at an average cost of $14.87 per share, for a total transaction of $497,178.45. Following the transaction, the chief executive officer owned 20,742,935 shares of the company’s stock, valued at $308,447,443.45. This represents a 0.16% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.